Загрузка...
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
BACKGROUND: Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban treatment o...
Сохранить в:
| Опубликовано в: : | Cancer Med |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6434207/ https://ncbi.nlm.nih.gov/pubmed/30767432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1997 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|